A novel therapeutic strategy for advanced locoregional melanomas using anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) immunotherapy has shown efficacy as a preoperative treatment to enhance cure rates and shorten the duration of systemic therapy [5]. This evidence concerns the gene CTLA4 and melanoma.